Vaccine adjuvant technology: From mechanistic concepts to practical applications

Expert Review of Vaccines

Volumn 2, Issue 2, 2003, Pages 327-335

  Degen, Winfried G J ^a   Jansen, Theo ^a   Schijns, Virgil E J C ^a  

^a INTERVET INTERNATIONAL BV   (Netherlands)

Author keywords

Adjuvant; Controlled release; Costimulation; Dendritic cells; Differential gene expression; Emulsion; Genomics; Micro array; Veterinary

Indexed keywords

ALUMINUM HYDROXIDE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; VIRUS VECTOR; WATER OIL CREAM;

ANTIGEN PRESENTING CELL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG SAFETY; GENE EXPRESSION; GENOMICS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL; VISCOSITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; BIOLOGICAL PRODUCTS; DRUG DESIGN; EMULSIONS; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; LYMPHOCYTE ACTIVATION; SAFETY; VACCINES;

EID: 0037992566     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.2.327     Document Type: Review

References (55)

1. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symp. Quant. Biol. 54, 1-13 (1989).
2. Schijns VEJC. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12, 456-463 (2000).
3. Schijns VEJC. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol. 21, 75-85 (2002).
4. Steinman RM, Metlay J, Bhardwaj N et al. In: Dendritic cells: Nature's adjuvant. Janeway CA Jr, Sercarz EE, Sprent J (Eds.) Alan R. Liss/Wiley & Sons, New York, NY, USA, 155-165 (1998).
5. Bretscher P, Cohn M. A theory of self-non-self discrimination. Science 169, 1042-1049 (1970).
6. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengarten H. Antigen localization regulates immune responses in a dose- and time-dependent fashion: a geographical view of the immune system. Immunol. Rev. 156, 199-209 (1997).
7. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin. Immunol. 12, 163-171 (2000).
8. Karrer U, Althage A, Odermatt B et al. On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox -/-) mutant mice. J. Exp. Med. 185, 2175-2170 (1997).
9. Ochsenbein AF, Linschewer DD, Odermatt B, Ciurrea A, Hengartner H, Zinkernagel RM. Correlation of T-cell independence of antibody responses with antigen dose reaching secondary lymphoid organs: Implications for splenectomized patients and vaccine design. J. Immunol. 164, 6296-6302 (2000).
10. Kündig TM, Bachmann MF, DiPaolo C et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268, 1343-1347 (1995).
11. Freund J, Casals J, Page-Hosmer E. Sensitization and antibody formatio after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med 37, 509-513 (1937).
12. Herbert WJ. Antigenicity of soluble protein in the presence of high levels of antibody: a possible mode of action of the antigen adjuvants. Nature 210, 7247-748 (1966).
13. Herbert WJ. The mode of action of mineral oil emulsion adjuvants on antibody production in mice. Immunology 14, 301-318 (1968).
14. Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13, 11-16 (1992).
15. Matzinger P. Tolerance, danger and the extended family. Ann. Rev. Immunol. 12, 991-1045 (1994).
16. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med 5, 1249-1252 (1999).
17. Bachmann MF, Kopf M. The role of B-cells in acute and chronc infections. Curr. Opion. Immunol. 11, 332-339 (1999).
18. Siegrist CA, Barrios C, Martinez X et al. Influence of maternal antibodies on vaccine response: inhibition of antibody but not T-cell responses allows succesful early primeboost strategies in mice. Eur. J. Immunol. 28, 4138-4148 (1998).
19. Morris W, Steinhoff MC, Russel PK. Potential of polymer microcapsulation technology for vaccine innovation. Vaccine 12, 5-11 (1994).
20. Langer R. New methods of drug delivery. Science 249, 1527-1533 (1990).
21. Le Moignic, Pinoy. Les vaccins en emulsion dans les corps gras ou 'lipo-vaccins'. Comptes Rendus Soc. Biol. 79, 201-203 (1916).
22. Freund J, Cascals J, Hosmer EP. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 37, 509-513 (1937).
23. Dupuis M, Murphy TJ, Higgins D et al. Dendritic cells internalize vaccine adjuvant after im. injection. Cell. Immunol. 186, 18-27 (1998).
24. Whitehouse MW, Orr KJ, Beck FWJ, Pearson CM. Freund's adjuvants: relationship of arthritogenicity and adjuvanticity in rats to vehicle composition. Immunology 27, 311-330 (1974).
25. Bromford R. The adjuvant activity of fatty acid esters. The role of acyl chain length and degree of saturation. Immunology 44, 187-192 (1981).
26. Shaw CM, Alvord EC, Keis MW, Straight chain hydrocarbons as substitutes for the oil in Freund's adjuvants in the production of experimental 'allergic' encephalomyelitis in the guinea-pig. J. Immunol. 92, 24-27 (1964).
27. Yip HC, Karulin AY, Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162, 3942-3949 (1999).
28. Jankovic D, Liu Z, Gause WC. Th-1 and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol. 22, 450-457 (2001).
29. Lascelles AK, Eagleson G, Beh KJ, Watson DL. Significance of Freund's adjuvant/antigen injection granuloma in the maintenance of serum antibody response. Vet. Immunol. Immunopathol. 22, 15-27 (1989).
30. Florence AT, Law TK, Whateley TL. Nonaqueous foam structures from osmotically swollen W/O/W emulsion droplets. J. Colloid Interface Sci. 107, 584-588 (1985).
31. Garti N, Aserin A, Cohen Y. Mechanistic Considerations on the release of electrolytes from multiple emulsions stabilised by BSA and nonionic surfactants. J. Controlled Release 29, 41-51 (1994).
32. Bjerregaard S, Söderberg I, Vermehren C, Frokjaer S. Formulation and evaluation of release and swell mechanism of a water-inoil emulsion using factorial design. Int. J. Pharm. 193, 1-11 (1999).
33. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 19, 2666-2672 (2001).
34. McKercher PD, Oil adjuvants: Their use in veterinary biologics. In: Advances in carriers and adjuvants for veterinary biologics. Nervig RM, Gough PM, Kaeberle ML et al. (Eds). Iowa State University Press, Ames, USA, 115-128 (1986).
35. Murray R, Cohen P, Hardegree MC. Mineral oil adjuvants: biological and chemical studies. Ann. Allergy 30, 146-151 (1972).
36. Tengerdy RP, Lacetera NG. Vitamin E adjuvant formulations in mice, Vaccine 9, 204-206 (1991).
37. Page WF, Norman JE, Benenson AS. Long-term follow-up of army recruits immunized with Freund's incomplete adjuvanted vaccine. Vaccine Res. 2, 141-149 (1993).
38. De Luka M, Groosiord JL, Medard JM, Vaution C, Seiller M. A stable W/O/W multiple emulsion. Cosmetics Toiletries 105, 65-66 (1990).
39. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 19, 4363-4372 (2001).
40. Min W, Lillehoj HS, Burnside J, Weining KC, Staeheli P, Zhu JJ. Adjuvant effects of IL-1β, IL-2, IL-8, IL-15, IFN-alpha, IFN-γ TGF-β4 and lymphotactin on DNA vaccination against Eimeria acervulina. Vaccine 20, 267-274 (2001).
41. Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus Type 2 in vivo. J. Virol. 74, 11173-11180 (2000).
42. Leutenegger CM, Boretti FS, Mislin CN et al. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif. J. Virol. 74, 10447-10457 (2000).
43. Schijns VEJC, Weining KC, Nuijten P, Rijke EO, Staeheli P. Immunoadjuvant activities of E coli- and plasmid-expressed recombinant chicken IFN-α/β, IFN-γ and IL-1beta in 1-day- and 3-week-old chickens. Vaccine 18, 2147-2154 (2000).
44. Nobiron I, Thompson I, Brownlie J, Collins ME. Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice. Vaccine 19, 4226-4235 (2001).
45. Scheerlinck JP, Casey G, McWaters P et al. The immune response to a DNA vaccine can be modulated by co-delivery of cytokine genes using a DNA prime-protein boost strategy. Vaccine 19, 4053-4060 (2000).
46. Nohria A, Rubin RH. Cytokines as potential vaccine adjuvants. Biotherapy 7, 261-269 (1994).
47. Kim JJ, Bagarazzi ML, Trivedi N et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat. Biotechnol. 15, 641-646 (1997).
48. Staudt LM, Brown PO. Genomic views of the immune system. Ann. Rev. Immunol. 18, 829-859 (2000).
49. Harris AJ, Shaddock JG, Manjanatha MG, Lisenbey JA, Casciano DA. Identification of differentially expressed genes in aflatoxin B 1-treated cultured primary rat hepatocytes and Fischer 344 rats. Carcinogenesis 19, 1451-1458 (1998).
50. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470 (1995).
51. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257, 967-971 (1992).
52. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res. 22, 5640-5648 (1994).
53. Lisitsyn N, Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. Science 259, 946-951 (1993).
54. Diatchenko L, Lau YF, Campbell AP et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc. Natl. Acad. Sci. USA 93, 6025-6030 (1996).
55. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3, 15-24 (2001).